RxDoctor Payments Data

Michael Voehl, PA

Medical · Hagerstown, MDNPI 1891382982

Payments from drug & device makers

$939in general payments, 2019–2025

Across 39 payments — averaging $24.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$279
  • Esperion Therapeutics, Inc.$188
  • Pfizer$92
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$91
  • Boston Scientific$83
  • Bayer$42
  • plus $165 from 7 others

What the payments were for

  • Food & beverage$939100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$939 in reported general payments places this provider in the 65th percentile of 543 medical providers in Maryland.

See all medical providers in Maryland

Medicare billing

Part B allowed, 2024
$48,704
Medicare patients
318
Services billed
781

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban1,243$1,536,151
XareltoRivaroxaban317$400,902
EntrestoSacubitril/Valsartan189$207,027
Repatha SureclickEvolocumab56$77,008
JardianceEmpagliflozin49$51,446
BrilintaTicagrelor36$32,560
VascepaIcosapent Ethyl31$26,669
FarxigaDapagliflozin Propanediol15$22,769
Praluent PenAlirocumab17$18,082
Metoprolol Succinate945$16,774
NexlizetBempedoic Acid/Ezetimibe14$15,709
Dabigatran EtexilateDabigatran Etexilate Mesylate35$11,995
Atorvastatin Calcium819$10,714
Rosuvastatin Calcium383$10,017
Diltiazem 24hr Er (Cd)Diltiazem Hcl263$8,835

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$92$1,536,1511,243 claims
Johnson & JohnsonXarelto$17$400,902317 claims
Boehringer IngelheimJardiance, Pradaxa$33$56,04360 claims
Esperion Therapeutics, Inc.Nexlizet$188$15,70914 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 543 medical providers in Maryland.

Other medical in Hagerstown

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →